Variable Interval Versus Set Interval Aflibercept for DME (EVADE)
Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study)
Sponsor: California Retina Consultants
Listed as NCT02392364, this PHASE4 trial focuses on Cystoid Macular Edema and Diabetic Macular Edema and remains completed. Sponsored by California Retina Consultants, it has been updated 8 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE4
▶ Show 3 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- California Retina Consultants
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .